Merck Exercised the Option for the Global Rights of Abbisko Therapeutics's Pimicotinib

Merck Exercised the Option for the Global Rights of Abbisko Therapeutics's Pimicotinib

SHANGHAI, April 1, 2025 /PRNewswire/ -- On April 1, 2025, Beijing Time, Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics") announced that Merck has exercised the global commercialization option for pimicotinib (ABSK021), with an option exercise...

EPWK HOLDINGS LTD. Announces Full Exercise of Underwriters' Over-Allotment Option

EPWK HOLDINGS LTD. Announces Full Exercise of Underwriters' Over-Allotment Option

XIAMEN, China, Feb. 22, 2025 /PRNewswire/ -- EPWK HOLDINGS LTD. (the "Company") (NasdaqGM: EPWK), a company that connects businesses with great talents through innovative and efficient cloud-sourcing platforms, today announced that the underwriters...

Nona Biosciences Announces Update on Its Collaborator DualityBio's Antibody-Drug Conjugate (ADC) Collaboration with BeiGene

Nona Biosciences Announces Update on Its Collaborator DualityBio's Antibody-Drug Conjugate (ADC) Collaboration with BeiGene

CAMBRIDGE, Mass., Jan. 3, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to ITM), today announced that BeiGene. Ltd. has exercised its exclusive option to acquire global...

Duality Biologics Announces B7H4 ADC Milestone Achievement and License Exercise by BeiGene

Duality Biologics Announces B7H4 ADC Milestone Achievement and License Exercise by BeiGene

SOMERSET, N.J., SHANGHAI and SUZHOU, China, Dec. 31, 2024 /PRNewswire/ -- Duality Biologics ("DualityBio") announced that, BeiGene. Ltd. has exercised its exclusive option for the B7H4 antibody-drug conjugate (ADC) DB1312/BG-C9074 from DualityBio,...

menu
menu